Registry for Immunotherapy (BRIT) is a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK. BRIT is being rapidly adopted by immunotherapy centres across the United Kingdom.
Immunotherapy is a form of specialised treatment that can harness the immune system and reduce symptoms of a wide range of allergic and non-allergic diseases. BRIT focuses on immunotherapy by injection or by mouth for pollen and mite allergies, treatment of wasp and bee venom reactions, and the use of omalizumab (Xolair, Novartis) injections for chronic urticaria.
There is a huge need to understand the effects immunotherapy has on patient outcomes. Although clinical research trials have shown benefit, it’s important that we can see this too when treating patients in the “real world” in clinic. Many registries are simply a place to put data for others to use but BRIT is not like that, there are lots of direct benefits for patients and clinicians:
The first BRIT report has been created with the support of charities Anaphylaxis Campaign and Allergy UK and funded by ALK Abello, Allergy Therapeutics and Stallergenes Greer with an unrestricted educational grant. BSACI operates the Registry for Allergy & Clinical Immunology in partnership with Dendrite Clinical Systems Limited. The Society gratefully acknowledges the assistance of Dendrite Clinical Systems for: building, maintaining & hosting the web registry, data analysis and publishing the first report.
This report is a fantastic start at demonstrating just what we can achieve. I look forward to all of us being active contributors to what will no doubt be considered, in a few years’ time when we look back, as a real watershed moment for our specialty.
Professor Adam Fox, BSACI Former President
Adult Participant Consent Pack
Parent/Child Consent Pack (Scotland)